Volrustomig
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Locally Advanced Cervical Cancer
Conditions
Locally Advanced Cervical Cancer
Trial Timeline
Mar 31, 2025 → Mar 30, 2029
NCT ID
NCT06943833About Volrustomig
Volrustomig is a phase 2 stage product being developed by AstraZeneca for Locally Advanced Cervical Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT06943833. Target conditions include Locally Advanced Cervical Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06943833 | Phase 2 | Active |
| NCT06129864 | Phase 3 | Recruiting |
| NCT06079671 | Phase 3 | Recruiting |
Competing Products
20 competing products in Locally Advanced Cervical Cancer